RYTM Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -103.5% compared to Rhythm Pharmaceuticals's net margin of -886.28%. Rhythm Pharmaceuticals's return on equity of -178.94% beat Cytokinetics's return on equity of --.

Rhythm Pharmaceuticals has a consensus price target of $75.08, signalling upside risk potential of 47.31%. On the other hand Cytokinetics has an analysts' consensus of $79.10 which suggests that it could grow by 78.31%. Given that Cytokinetics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Cytokinetics is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.300, which suggesting that the stock is 130.019% more volatile than S&P 500. In comparison Cytokinetics has a beta of 0.949, suggesting its less volatile than the S&P 500 by 5.057%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $41.8M, which are larger than Cytokinetics quarterly revenues of $16.9M. Rhythm Pharmaceuticals's net income of -$43.3M is higher than Cytokinetics's net income of -$150M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 23.89x versus 268.32x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Geron has a net margin of -103.5% compared to Rhythm Pharmaceuticals's net margin of -53.33%. Rhythm Pharmaceuticals's return on equity of -178.94% beat Geron's return on equity of -59.29%.

Rhythm Pharmaceuticals has a consensus price target of $75.08, signalling upside risk potential of 47.31%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 174.39%. Given that Geron has higher upside potential than Rhythm Pharmaceuticals, analysts believe Geron is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.300, which suggesting that the stock is 130.019% more volatile than S&P 500. In comparison Geron has a beta of 0.535, suggesting its less volatile than the S&P 500 by 46.549%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $41.8M, which are smaller than Geron quarterly revenues of $47.5M. Rhythm Pharmaceuticals's net income of -$43.3M is lower than Geron's net income of -$25.4M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 23.89x versus 13.76x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

MannKind has a net margin of -103.5% compared to Rhythm Pharmaceuticals's net margin of 9.67%. Rhythm Pharmaceuticals's return on equity of -178.94% beat MannKind's return on equity of --.

Rhythm Pharmaceuticals has a consensus price target of $75.08, signalling upside risk potential of 47.31%. On the other hand MannKind has an analysts' consensus of $10.00 which suggests that it could grow by 92.31%. Given that MannKind has higher upside potential than Rhythm Pharmaceuticals, analysts believe MannKind is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.300, which suggesting that the stock is 130.019% more volatile than S&P 500. In comparison MannKind has a beta of 1.266, suggesting its more volatile than the S&P 500 by 26.58%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. MannKind pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $41.8M, which are smaller than MannKind quarterly revenues of $76.8M. Rhythm Pharmaceuticals's net income of -$43.3M is lower than MannKind's net income of $7.4M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while MannKind's PE ratio is 52.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 23.89x versus 5.34x for MannKind. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -103.5% compared to Rhythm Pharmaceuticals's net margin of 24.22%. Rhythm Pharmaceuticals's return on equity of -178.94% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Rhythm Pharmaceuticals has a consensus price target of $75.08, signalling upside risk potential of 47.31%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Rhythm Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe Rhythm Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.300, which suggesting that the stock is 130.019% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $41.8M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Rhythm Pharmaceuticals's net income of -$43.3M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 23.89x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.